- Home
- TRU vs INCY Comparison
TRU vs INCY Comparison
Compare TRU & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | INCY |
|---|---|---|
| Founded | 1968 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 17.0B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TRU | INCY |
|---|---|---|
| Price | $72.58 | $94.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $92.27 | ★ $104.05 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | 60.00 | ★ 4173.33 |
| EPS | 2.32 | ★ 6.41 |
| Revenue | ★ $4,576,300,000.00 | $3,394,635,000.00 |
| Revenue This Year | $11.20 | $10.44 |
| Revenue Next Year | $8.00 | $10.99 |
| P/E Ratio | $31.48 | ★ $14.89 |
| Revenue Growth | 9.38 | ★ 13.67 |
| 52 Week Low | $65.24 | $57.77 |
| 52 Week High | $99.39 | $112.29 |
Technical Indicators
Market Signals| Indicator | TRU | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 47.04 |
| Support Level | $70.43 | $93.54 |
| Resistance Level | $75.82 | $108.79 |
| Average True Range (ATR) | 2.84 | 2.36 |
| MACD | 0.33 | 0.07 |
| Stochastic Oscillator | 43.11 | 23.39 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.